Tagomics Unveils Co-Marketing Initiative with Agilent
Deal News | Nov 20, 2024 | Illumina Ventures
In a strategic move to enhance biomarker discovery and diagnostics, Tagomics Ltd. has announced a collaboration with Agilent Technologies. This partnership allows a select group of customers to access their combined offerings, leveraging Tagomics' novel Interlace multiomics platform and Agilent's SureSelect Library Preparation and Target Enrichment System. Tagomics' Interlace platform specializes in epigenetic profiling, enriching unmethylated DNA without altering the DNA sequence. It integrates seamlessly with genome and targeted sequencing to analyze a range of features. Agilent's comprehensive genomic solutions enable the detection of various somatic variants in solid tumors, complementing Tagomics' offerings. This strategic alliance promises to provide deeper insights into disease mechanisms and foster the development of new diagnostic and therapeutic avenues.
Sectors
- Biotechnology
- Genomics
Geography
- United Kingdom – Tagomics' service lab, where the technology access program is hosted, is located in Cambridge, UK.
Industry
- Biotechnology – The article focuses on biomarker discovery and diagnostics, leveraging biotechnological advancements for disease insights.
- Genomics – Agilent Technologies is a major player in the genomics tools sector, and the focus on genomic and epigenomic profiling highlights this industry's relevance.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Tagomics Ltd. | Target company | Company | Pioneering biomarker discovery and diagnostics company. |
| Agilent Technologies | Collaborating company | Company | Leading provider of tools in the genomics sector. |
| Illumina Ventures | Private Equity Firm | Company | PE firm backing Tagomics. |
| Dr Jack Kennefick | CEO and co-founder of Tagomics | Person | Executive leading Tagomics and driving the strategic partnership. |